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Abstract
Improving clinical outcomes among high risk Class III b thalassemia major patients (Class IIIHR) receiving an allogeneic SCT
remains a challenge. From October, 2009 a treosulfan based regimen (TreoFluT) was used for all consecutive Class III
patients (n = 50). The clinical outcomes were compared with the historical conventional busulfan (BuCy) based regimen
(n = 139). Use of TreoFluT was associated with a significantly reduced incidence of sinusoidal obstruction syndrome (SOS)
among Class IIIHR cases (78% to 30%; P = 0.000) and early TRM (46% to 13%; p = 0.005). There was also a trend towards
better engraftment in the Class IIIHR subset (P = 0.055). However, the use of bone marrow (BM) as source of stem cells along
with the TreoFluT regimen was associated with 50% early mixed chimerism which reduced to 8.5% with the use of a
peripheral blood stem cell graft (PBSC). Use of a PBSC graft was not associated with a significant increase in the incidence of
acute or chronic graft versus host disease (GVHD). The overall and event free survival was significantly better among the
Class IIIHR subset with the use of TreoFluT Vs. BuCy (86.667.3 Vs. 39.466.8%; P = 0.002 and 77.868.8 Vs. 32.466.5%;
P = 0.003 respectively). A TreoFluT conditioning regimen with a PBSC graft can significantly improve clinical outcomes of
Class IIIHR patients.
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Introduction
Allogeneic stem cell transplantation (SCT) remains the only
curative option for patients with b thalassemia major. The
correction of this disorder by an allogeneic stem cell transplant
was first described by Thomas et al [1]. Subsequently, a
myeloablative conditioning regimen of busulfan and cyclophos-
phamide was established and has been the standard of care for
stem cell transplantation in this condition [2]. The current risk
stratification [3,4] of patients with b thalassemia major undergoing
a myeloablative allogeneic stem cell transplantation (SCT) has
significant limitations and fails to recognize a very high risk group.
Prior to stem cell transplant patients who were $7 years old and
had a liver size $5 cms constitute what we previously defined as a
very high risk subset of a conventional high risk Class III group
(Class III high risk or Class IIIHR) [5]. The adverse impact of age
and liver size was further validated by an international collabo-
rative analysis which was recently reported [6]. Class III and more
specifically Class III high risk (HR) subset have a high risk of graft
rejection and regimen related toxicity especially sinusoidal
obstruction syndrome (SOS) leading to multi-organ failure and
death. The poor clinical outcome in this subset of older patients
with very poor pre-transplant medical therapy, as reported by us,
is not reflected in the Western literature due to the use of adequate
blood transfusion and chelation support prior to transplant.
However, when such a population is transplanted even in a
developed country with expertise in such transplants the rejection
rate is as high as 34% [7].
This has lead to the evaluation of a number of novel
conditioning regimens in this group [3,4,8,9,10,11]. Treosulfan
(dihydroxybusulfan), in the recent past, has attracted a lot of
attention as an agent to replace busulfan in view of its favorable
toxicity profile [12]. It is especially attractive in the context of an
allogeneic SCT for high risk b thalassemia major because of its
reported low hepatic toxicity profile and consistent pharmacoki-
netic profile which are both significant problems with conventional
busulfan in this population [5,13,14]. Bone marrow has been the
preferred choice of stem cells to reduce the risk of graft versus host
disease (GVHD) in this non malignant condition, though the
incidence of both acute and chronic GVHD in this predominantly
pediatric population is low [14,15]. Recently a similar low
incidence of acute and chronic GVHD with a PBSC graft in the
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setting of matched unrelated transplants has been reported from
China [16].
We report our experience of allogeneic SCT in Class III and the
Class IIIHR subset and the impact of the use of a previously
reported reduced toxicity Treosulfan based regimen [11,17]
modified by the use of peripheral blood stem cell (PBSC) graft.
Materials and Methods
This is a retrospective analysis of anonymous patient data. All
data was taken from patient records at the Christian Medical
College and Hospital, and this study was approved by the ethical
review board of Christian Medical College.
All consecutive transfusion dependant b thalassemia patients
with a HLA identical related donor or a $9 of 10 high resolution
HLA matched unrelated donor who underwent an allogeneic SCT
at our centre from October, 1991 to February, 2012 were included
in this analysis.All patents and donors underwent the procedure
after getting written and informed consent. The consent forms and
consent procedure was approved by the institutions review board.
Hard and soft copies of the consent form and all the data
generated from the transplant procedure on patients and donors is
filed permanently in our department.
Pre-transplant evaluation
All patients were evaluated with a complete blood count (CBC),
biochemical profile and serology for HIV, HBV, HCV and CMV.
Pre-transplant a liver biopsy was performed at the time of
Hickman catheter insertion.
Conditioning
Conditioning regimensin the majority was a myeloablative
regimen consisting of a combination of busulfan and cyclophos-
phamide (BuCy) as previously reported by us [14]. From October,
2009 till to date, in an effort to reduce the treatment related
morality (TRM) and graft rejection in our high risk cases, the
conditioning regimen was modified. This involved the use of a
Treosulfan based conditioning regimen as previously reported
[11,17]and consisted of administering thiotepa 8 mg/kg on day -6,
fludarabaine 30 mg/m2/day64 days from day-5 to -2 and
treosulfan 14 gm/m263 days from day-5 to -3 (TreoFluT).
Bone Marrow Harvest
Until the introduction of a TreoFluT conditioning regimen in
October 2009 the stem cell source was bone marrow (BM) alone for
the majority of patients (98.7%). Bone marrow was harvested under
general anesthesia from the iliac crest and the target cell dose was
66108 nucleated cells/Kg body weight of the recipient. The harvest
was collected in ACD with preservative free heparin using one-liter
harvest bags. For major ABO mismatched transplants, red cell
depletion was achieved with 6% hydroxyethyl starch and gravity
sedimentation. After the introduction of the treosulfan conditioning
regimen in October, 2009 the stem cell source initially continued to
be BM until October, 2010. Due to increased concerns of early
mixed chimerism and graft rejection the stem cell source was
changed PBSC for all Class III patients who were conditioned with
a TreoFluT based regimenfrom November, 2010. The stem cell
products were administered soon after harvest or processing.
GVHD prophylaxis
Cyclosporine and short course methotrexate was used as
GVHD prophylaxis; cyclosporine was administered at a dose of
2.5 mg/Kg intravenously over four hours twice daily starting on
day –4 and changed to oral administration at 5 mg/Kg twice daily
when mucositis had resolved. Cyclosporine levels were monitored
and the dose adjusted to achieve a target level of 100–300 ng/ml.
The methotrexate dose was 10 mg/m2 on day +1 and 7 mg/m2
on day 3, 6 and 11. Acute GVHD was treated with dexameth-
asone or methyl prednisone. Steroid refractory GVHD was treated
as per the discretion of the treating physician.
Chimerism Analysis
Analysis of chimerism and quantification of recipient and donor
in samples was done by polymerase chain reactionamplification of
informative STR or VNTR followed by gene scan analysis as has
been previously reported by us [18].
Supportive care
All patients were nursed in a positive pressure HEPA filtered
transplant unit. None of the patients received prophylactic antibiotics
or underwent gut decontamination. Prophylactic acyclovir was
administered for the first 100 days; it was continued beyond day 100
if patient had GVHD and required additional immuno-suppression.
Trimethoprim-sulphamethoxazole and oral penicillin prophylaxis was
initiated after stable engraftment and continued for a year. At the end
of one year all patients who did not have evidence of GVHD and were
off all immunosuppressive drugs were vaccinated against polio,
diphtheria, tetanus, hemophilus influenza and pneumococcus.
Definitions
Incidence and severity of GVHD was defined as per established
criteria [19]. Hepatic sinusoidal obstruction syndrome (SOS) was
diagnosed according to Baltimore criteria [20]. Mixed chimerism
for the purpose of this study was defined as #95% donor cell
percentage. Event free survival (EFS) was defined from the time of
transplant to an event; an event was primary graft rejection, death
or recurrence of transfusion dependence. Stable mixed chimerism
with transfusion independence was not considered an event for this
analysis. Overall survival (OS) was defined as time from transplant
to death due to any cause.
Statistical analysis
The x2, t test or fisher exact test and Mann Whitney U test were
used to compare differences between groups. Probabilities of event
free survival (EFS) and overall survival (OS) following transplant
were estimated by the Kaplan-Meier method and the significance
assessed by log-rank test. The relationships of clinical features to
outcome were analyzed by Cox proportional hazard model.Signi-
ficance levels were set at 0.05. Statistical analysis was done using
SPSS version 11.0.
Results
Demographic and Clinical Characteristics
A total of 362 patients with transfusion dependent b thalassemia
underwent an allogeneic SCT between January, 1991 and
February, 2012 at our centre. 358 (98.8%) of these transplants
were from related donors and of the related donors 348 (97.2%)
were HLA identical. The median age of this cohort was 764.4
years and there were 227 males (62.7%). There were 16(4.4%),
144 (39.8%) and 202 (55.8%) transplants in Lucarelli Class I, II
and III respectively.
Of the 202 Class III patients, 82 (40.5%) were classified as Class
IIIHR (Age$7 years and liver size$5 cms). The conditioning
regimen used for the Class III patients was BuCy in 139 (68.8%)
and TreoFluT in 50 (24.7%). Similarly, the 82 cases identified as
Class IIIHR were conditioned with BuCy in 54 (65.8%) and
TreoFluT in 24 (29.2%). The baseline characteristics and clinical
SCT for High Risk b Thalassemia and Treosulfan
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outcomes of Class III and Class IIIHR patients conditioned with
BuCy and TreoFluTregimens are summarized in Tables 1 and 2
respectively.With the exception of the significantly higher use of
PBSC grafts among those conditioned with the TreoFluT regimen
there were no other significant differences in baseline character-
istics among patients conditioned with these regimens among the
entire Class III (Table 1) and the Class IIIHR subset (Table 2).
Engraftment and day28 chimerism analysis
The proportion of patients who engrafted post-transplant was
higher with the TreoFluT based conditioning regimen (Table 1)
and this tended to statistical significance in the Class IIIHR subset
(Table 2: 78% Vs. 96% in favor of the TreoFluT group; P-
value0.055). The time to achieve a platelet count .206109/Lt
was significantly shorter with the TreoFluT conditioning regimen
for the entire Class III and the Class IIIHR subset (Table 1 and 2).
This was predominantly contributed by the use of a PBSC graft in
patients conditioned with TreoFluT as illustrated in Table 3. This
faster engraftment translated into significantly lower number of
platelet and packed red cell units (PRC) transfused in the peri-
transplant period (Table 1). Among patients conditioned with a
TreoFluT regimen the use of PBSC grafts was also associated with
significant reduction in peri-transplant platelet and PRC units
Table 1. Baseline characteristics, supportive care and clinical outcomes of Class III patients receiving different conditioning
regimens.
Variable
Bu/Cya (n =139) n(%)/Median
(range)/Mean ± SD
TreoFluTb (n =50) n(%)/Median
(range)/Mean ± SD P-value
Age 9 (2–24) 11 (2–21) 0.108
Sex: Male 87 (63) 30 (60) 0.738
Female donor to Male recipient (F.M) 50 (36) 14 (28) 0.384
HBsAg positive 5 (4) 1 (2) 1.000
HCV positive 28 (20) 7 (14) 0.401
CMV IgG positive 130 (96) 47 (94) 0.448
Liver Size (cms) 4.661.7 4.661.8 0.907
Splenectomy 30 (22) 8 (16) 0.537
ALT* (IU/Lt) 80 (10–357) 54 (8–230) 0.031
AST
ˆ
(IU/Lt) 56 (15–199) 45 (14–186) 0.143
Serum Ferritin (ng/ml) 4096 (681–13600) 4380 (1449–10950) 0.397
Number of packed cells transfused pre-transplant 120 (20–450) 119.5 (22–280) 0.653
Stem cell source:
BM@ 128 (92) 13 (26)
G-CSF primed BM 9 (7) - 0.000
PBSC# 2 (1) 37 (74)
CD34 (6106/kg) 6.7 (2.64–15.9) 11.4 (2–30) 0.000
Engraftment 122 (88) 47 (94) 0.289
Engraftment (days):
Time to ANC.0.56109/Lt 16.964.1 16.163.2 0.242
Time to platelet.206109/Lt 32.7617.6 18.868.0 0.000
Peri-transplant support:
(up to day 100)
Platelet units transfused 23 (5–92) 13 (1–76) 0.000
PRCh units transfused 19 (0–357) 13 (1–91) 0.003
Sinusoidal obstruction syndrome 92 (66) 11 (22) 0.00
Graft Rejection 16 (12) 4 (8) 0.599
Graft versus host disease:
Acute GVHD 55 (44) 17 (35) 0.305
Chronic GVHD 17 (18) 4 (11) 0.430
Treatment related mortality(,day 100) 39 (28) 6 (12) 0.021
Overall Survival 3 yrs‘ 63.664.2 87.464.8 0.011
Event free survival 3 yrs‘ 57.364.3 78.866.0 0.041
aBuCy: Busulfan + Cyclophosphamide; *ALT: Alanine aminotransferase.
bTreoFluT: Treosulfan, fludarabine and thiotepa;ˆAST: Aspartate aminotransferase.
@BM: Bone marrow; #PBSC: Peripheral blood stem cells.
hPRC: Packed red cell units; GVHD: graft versus host disease.
‘3 yrs. 3 years Kaplan-Meier estimate61SE%.
doi:10.1371/journal.pone.0061637.t001
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transfusedin comparison to those that received a BM graft
(Table 3).
The early experience with the TreoFluT regimen using a BM
graft (n = 13) resulted in 6 (50%) of evaluated patients (one died
prior to day 28) having mixed chimerism. For recipients with
mixed chimerism intervention with rapid withdrawal of cyclo-
sporine and donor lymphocyte infusion was considered when serial
chimerism values showed a downward trend with no evidence of
graft versus host disease (GVHD) or if the recipient became
transfusion dependent in the absence of evidence of post-
transplant pure red cell aplasia. Of the 6 cases with mixed
chimerism 2 went on to complete rejection (day 74 and day 76)
while 4 were salvaged with these interventions (2 received DLI).
Following this experience the graft source was changed to PBSC
for Class III patients conditioned with TreoFluT. With the use of
PBSC (n= 37), mixed chimerism was seen in 3 (8.5%) of the 35
patients evaluated (2 died prior to day 28). Of these three, one
patient was a 20 year old man who underwent a 9/10 MUD
transplant. This patient had a documented parvovirus B19
infection on day 15 and went on to have a primary graft failure
with autologous recovery. The remaining two cases were salvaged
with rapid tapering of immunosuppression and infusion of DLI.
Figure 1A summarizes the day 28 chimerism data among patients
receiving a TreoFluT conditioning regimen. The number of cases
Table 2. Baseline characteristics, supportive care and clinical outcomes of Class IIIHR (High Risk) group receiving different
conditioning regimens.
Variable
Bu/Cya(n =54) n(%)/Median
(range)/Mean ± SD
TreoFluTb (n =24) n(%)/Median
(range)/Mean ± SD P-value
Age 12 (7–24) 12 (3–21) 0.565
Sex: Male 31 (57) 16 (67) 0.466
Female donor to Male recipient (F.M) 19 (35) 5 (21) 0.289
HBsAg positive 3 (6) - 0.549
HCV positive 11 (20) 5 (21) 1.000
CMV IgG positive 52 (96) 22 (92) 0.097
Liver Size (cms) 6.261.4 6.161.2 0.770
Splenectomy 22 (41) 7 (29) 0.448
ALT*(IU/Lt) 106 (20–309) 49 (8–230) 0.008
AST
ˆ
(IU/Lt) 65 (18–199) 43.5 (14–186) 0.048
Serum Ferritin (ng/ml) 4537 (1528–11885) 4591 (1838–10710) 0.799
Number of packed cells transfused pre-transplant 152 (72–450) 150 (26–280) 0.422
Stem cell source:
BM@ 52 (96) 7 (29)
G-CSF primed BM 2 (4) - 0.000
PBSC# - 17 (71)
CD34 (6106/kg) 5.8 (2.9–14.8) 9.95 (2–30) 0.001
Engraftment 42 (78) 23 (96) 0.055
Engraftment (days):
Time to ANC.0.56109/Lt 17.065.1 15.863.4 0.503
Time to platelet.206109/Lt 35.4612.9 20610.2 0.000
Peri-transplant support:
(upto day 100)
Platelet units transfused 21 (5–92) 16.5 (1–76) 0.063
PRCh cell units transfused 18 (5–357) 13.5 (1–88) 0.020
Sinusoidal obstruction syndrome 42 (78) 7 (30) 0.000
Graft Rejection 7 (13) 2 (8) 0.713
Graft versus host disease:
Acute GVHD 23 (55) 8 (35) 0.194
Chronic GVHD 6 (21) 2 (11) 0.445
Treatment related mortality(,day 100) 25 (46) 3 (13) 0.005
Overall Survival 3 yrs‘ 39.466.8 86.667.3 0.002
Event free survival 3 yrs‘ 32.466.5 77.868.8 0.003
aBuCy: Busulfan + Cyclophosphamide; *ALT: Alanine aminotransferase.
bTreoFluT: Treosulfan, fludarabine and thiotepa;ˆAST: Aspartate aminotransferase.
@BM: Bone marrow; #PBSC:Peripheral blood stem cells.
hPRC: Packed red cell units; GVHD: graft versus host disease.
‘3 yrs. 3 years Kaplan-Meier estimate61SE%.
doi:10.1371/journal.pone.0061637.t002
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with mixed chimerism was higher and the median day 28
chimerism was significantly lower in patients receiving a BM graft
(Figure 1A).
Sinusoidal obstruction syndrome
There was significant reduction in incidence of SOS in Class III
patients (Table 1: P-value= 0.000) and Class IIIHR patients
(Table 2: P-value= 0.000)conditioned with a TreoFluTregimen.
Among Class IIIHR cases, those conditioned with BuCy had a 78%
incidence of SOS while those conditioned with the TreoFluT
regimen it was 30%. Of the 7(30%) Class IIIHR cases conditioned
with TreoFluT that had a documented SOS, it was mild self-
limiting and managed conservatively in 6 and in only one case did it
result in multi-organ failure leading to death. In contrast among
Class IIIHR cases conditioned with a BuCy regimen in 10 (24%) of
the 42 cases documented to have SOS this was the major
contributory cause of death. The low incidence of SOS and other
regimen related toxicity translated to a significantly lower day 100
treatment related mortality (TRM) among Class IIIHR patient
conditioned with TreoFluT (Table 2: 13%Vs. 46%; P-value-0.005).
Graft versus host disease
There was no significant difference in the incidence of acute or
chronic GVHD among Class III or Class IIIHR cases conditioned
with either regimens (Table 1 and 2 respectively). Among Class III
patient’s conditioned with a TreoFluT regimen who received
either a BM or a PBSC graft Grade 2–4 acute GVHD was seen in
3 (23%) Vs. 10 (27%)respectively while Grade 3–4 acute GVHD
was seen in none Vs. 3 (8.1%) respectively (Table 3). Of the 3
patients who developed Grade 3–4 acute GVHD among those
who received a PBSC graft, one patient responded to therapy and
has complete resolution of GVHD while the other two succumbed
to it.Among the 3 (12%) that developed chronic GVHD after a
TreoFluT conditioning regimen and PBSC graft(Table 3) it was
extensive in one while it was limited in the other two.
Survival
After excluding patients who had early TRM (,100 days) the
actuarial median follow up of this cohort was 42 months (range: 3–
254). The 3 year Kaplan-Meier estimate of OS and EFS of the
entire Class III cohort was 67.463.5% and 58.963.7% respec-
tively. Among the Class III patients use of a TreoFluT regimen
was associated with a significant improvement in OS and EFS (as
illustrated in Figure 1C and 1D) respectively. Similarly, the OS
and EFS were significantly superior in the Class IIIHR subset that
was conditioned with a TreoFluT regimen (illustrated in Figure 1E
and 1F respectively).
Table 3. Comparison of Class III patients who received TreoFluTconditioning with either a bone marrow or peripheral blood
source of stem cells.
Variable
BM@ (n=13) n(%)/Median
range)/Mean ± SD
PBSC# (n = 37) n(%)/Median
(range)/Mean ± SD P-value
Age 9 (6–14) 11 (2–21) 0.001
Sex: Male 10 (77) 20 (54) 0.197
Female donor to Male recipient (F.M) 4 (31) 10 (27) 1.000
CD34 (6106/kg) 8.8 (2.1–24.4) 12.5 (2–30) 0.000
Engraftment 12 (92) 35 (95) 1.000
Engraftment (days):
Time to ANC.0.56109/Lt 16.462.6 16.063.4 0.051
Time to platelet.206109/Lt 26.268.8 16.566.3 0.000
Chimerism:
Evaluated on Day 28: 12 (92.3) 35 (94.5) 0.720
Percentage donor cells 97.5 (52–100) 100 (0–100) 0.004
Mixed chimerism 6 (50%) 3 (8.5%) 0.005
Graft Rejection 2 (15) 2 (5) 0.275
Peri-transplant support:
(upto day 100)
Platelet units transfused 20 (10–31) 13 (1–76) 0.000
PRCh units transfused 17 (8–65) 12 (1–91) 0.001
Sinusoidal obstruction syndrome 5 (39) 6 (17) 0.133
Graft versus host disease 0.498
Acute GVHD 3 (23) 14 (39) 1.000
Chronic GVHD 1 (9) 3 (12)
Treatment related mortality(,day 100) 2 (15) 4 (11) 0.643
Overall Survival 3 yrs‘ 72.262.7 87.365.4 0.717
Event free survival 3 yrs‘ 65.962.8 73.9611.2 0.309
@BM: Bone marrow; #PBSC: Peripheral blood stem cells.
hPRC: Packed red cell units; GVHD: graft versus host disease.
‘3 yrs. 3 years Kaplan-Meier estimate61SE%3.
doi:10.1371/journal.pone.0061637.t003
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Figure 1. Analysis of day 28 chimerism and survival in different subsets. (A) Day 28 chimerism comparing patients conditioned with
aTreoFluT regimen and receivingeither a bone marrow graft (Treo BM) or a peripheral blood stem cell graft (Treo PBSC); NE = not evaluated; indicates
cases that had died prior to day 28 and were hence: not evaluated. m Filled triangles indicates cases that had an event defined as either graft
rejection or death.g Empty triangles indicate cases that did not have an event defined as either graft rejection or death (B) Overall survival of all Class
SCT for High Risk b Thalassemia and Treosulfan
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Cause of deaths
Among the Class III patients 39 (28%) of the cases conditioned
with a Bu/Cy regimen died while 6 (12%) of those conditioned
with a TreoFluT regimen died. Table 4 summarizes the major
contributory cause of death among these two groups. As illustrated
in table 4, SOS was a major contributing factor for death when
Bu/Cy was the conditioning regimenand was significantly lower
when a TreoFluT regimen was used. Deaths beyond day 100 was
seen in 12 (8.6%) of cases conditioned with Bu/Cy and the major
contributory cause was infections. Among those conditioned with
TreoFluT there were 2 (4%) deaths beyond day 100, both were
related to graft rejection and both had received a BM graft.
Discussion
Improving clinical outcomes of Class III and the Class IIIHR
[5] b thalassemia major following an allogeneic SCT remains a
challenge. We had previously reported the poor clinical outcome
of our newly recognized Class IIIHR subset following allogeneic
SCT using a conventional myeloablative Bu/Cy regimen [5].
The major contributory factors for the poor clinical outcome in
these patients were a combination of high risk for graft rejection
and regimen related toxicity (RRT) [5]. Early attempts to reduce
RRT in a similar cohort of cases were done by reducing the
cumulative dose of busulfan and cyclophosphamide. Experience
from such an approach, as reported by the Pesaro group,
suggested that a reduction in TRM was achieved but there was
a significantly higher risk of graft rejection [10]. While other
regimens have been reported to improve the clinical outcome of
Class III thalassemia patients undergoing an allogeneic SCT [9]
we would argue that most published data does not address the very
high risk subset as defined by us [5]. The clinical outcome of a
similar cohort reported from a developed country center would
suggest that one could anticipate a graft rejection close to 34% [7]
with intravenous busulfan in spite of pharmacokinetic monitoring
and appropriate dose modifications.
We were particularly attracted to the treosulfan based regimen
due to the low hepatotoxicity profile of this agent [12] and the
reported low incidence of SOS in patients with thallasemia major
[11,17]. Hepatic SOS was a major problem with a conventional
myeloablative regimen in our Class IIIHR patients with 78% of
cases developing this complication and in 24% of such cases it lead
to multi-organ failure and death.
Our initial experience with this TreoFluT regimen with a BM
graft in this cohort at a very high risk for graft rejection was
concerning, with 6 (50%) having early mixed chimerism. Our
experience and reported data would suggest that early mixed
chimerism, unlike late stable mixed chimerism, usually predicts
secondary graft rejection in up to 50% of these cases [21]. Four of
these initial 6 cases of mixed chimerism were salvaged with rapid
taper of immune-suppression (2 of these required additional DLI
to restore transfusion independence). The regimen itself was very
well tolerated. We then opted to use a PBSC graft source with the
same conditioning regimen. This approach resulted in greater
consistency of early complete chimerism and was associated with
additional benefits such as faster engraftment and significantly
reduced peri-transplant transfusion support. Use of a PBSC graft
did not result in a significantly higher incidence of acute or chronic
GVHD compared to a BM graft with the same regimen. Chronic
GVHD remains a concern with the use of a PBSC graft and this is
one of the reasons why we have restricted the use of this regimen
along with a PBSC graft to Class III patients.
Unfortunately, in resource constrained environments, such as
ours and many other developing countries, it is not uncommon for
a majority of patients with b thalassemia major to present late for
transplantation. The body mass index (BMI) of our Class III
patients is reflective of the poor clinical condition of a majority of
these patients with the median BMI being 14.9 (range: 10.2–23.8)
(figure S1). Only 22 (10.9%) of our Class III patients had a BMI in
the normal range.
This retrospective data analysis is limited by the comparison of
the use of TreoFluT regimen with a historical control spanning
more than two decades. However, as illustrated in figure S2 the
clinical outcome analyzed by 5 year intervals since the start of our
transplant program reflects that there has been marginal,
statistically not significant, improvement in the event free survival
of our Class III or Class IIIHR cases over this time period. This
illustrates that improvements in techniques and supportive care
cannot explain the improved outcome seen with this treosulfan
based regimen in our center.
In summary, this data suggests that even in a very high risk
group of b thalassemia major patients undergoing an allogeneic
SCT the benefits of this TreoFluT regimen along with a PBSC
graft outweighs the risks and can significantly improve the overall
and event free survival.
Supporting Information
Figure S1 Body mass index of Class III patients.
(DOCX)
III patients conditioned with either a TreoFluT (Treo) or a busulfan based regimen (Bu/Cy) (C) Event free survival of all Class III patients conditioned
with either a TreoFluT (Treo) or a busulfan based regimen (Bu/Cy) (D) Overall survival of all Class IIIHR patients conditioned with either a TreoFluT
(Treo) or a busulfan based regimen (Bu/Cy) (E) Event free survival of all Class IIIHR patients conditioned with either a TreoFluT (Treo) or a busulfan
based regimen (Bu/Cy).
doi:10.1371/journal.pone.0061637.g001
Table 4. Comparison of major contributory cause of early
death (death ,100 days post transplant) among Class III
patients.
Variable Bu/Cya n=139 Treob n=50 P-value
Died , day 100 39 (28%) 6 (12%) 0.001
Rejection 5 (3.6%) - 0.581
Sinusoidal obstruction
syndrome
17 (12.1%) 1 (2%) 0.035
Infection 7 (5%) 2 (4%) 0.768
DAH# 2 (1.4%) - 0.394
Cardiac failure 2 (1.4%) 1 (2%) 0.798
Hemorrhagic cystitis 1 (0.7%) - 0.548
GVHD 2 (1.4%) 2 (4%) 0.281
Intra-cerebral bleed 3 (2.1%) - 0.295
aBuCy Busulfan + Cyclophosphamide.
bTreoFluT Treosulfan, fludarabine and thiotepa.
#DAH Diffuse alveolar hemorrhage.
GVHD Graft versus host disease.
doi:10.1371/journal.pone.0061637.t004
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Figure S2 Event free survival of (A) Class III and (B)
Class IIIHR over different time periods of allogeneic
stem cell transplantation at our center.
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